← All Arcutis Biotherapeutics, INC filings

Arcutis Biotherapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ARQT
Arcutis Biotherapeutics, INC
10-K: Arcutis Sees Strong ZORYVE Sales, Narrows Losses in 2025
Arcutis Biotherapeutics reports significant revenue growth for its ZORYVE product line in 2025, driven by expanded indications and commercial launches, despite ongoing net losses and a terminated promotion agreement.
NASDAQ
ARQT
Arcutis Biotherapeutics, INC
10-K: Arcutis Biotherapeutics Reports Full Year 2024 Results, Highlights ZORYVE Growth and Pipeline Advancement
Arcutis Biotherapeutics reports increased product revenue driven by ZORYVE sales, alongside continued investment in research and development for its dermatology pipeline.
NASDAQ
ARQT
Arcutis Biotherapeutics, INC
10-K: Arcutis Biotherapeutics Reports Full Year 2023 Results, Highlights Commercial Progress and Pipeline Advancements
Arcutis Biotherapeutics' 2023 annual report details commercial growth of ZORYVE, pipeline progress, and financial challenges including a minimum financing covenant.